References
- Abu-Amero KK, Wyngaard CA, Dzimiri N. (2003). Prevalence and role of methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms in coronary artery disease in Arabs. Arch Pathol Lab Med 127:1349–1352.
- Acacio G, Barini R, Bertuzzo C, Couto C, Annichino-Bizzacchi J, Junior W. (2005). Methylenetetrahydrofolate reductase gene polymorphisms and their association with trisomy 21. Prenat Diagn 25:1196–1199.
- Bagley PJ, Selhub J. (1998). A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95:13217–13220.
- Borsa J, Whitmore GF. (1969). Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res 29:737–744.
- Castro R, Rivera I, Ravasco P, Camilo ME, Jakobs C, Blom HJ, de Almeida IT. (2004). 5,10-methylenetetahydrofolate reductase (MTHFR) 677C>T and 1298A>C mutations are associated with DNA hypomethylation. J Med Genet 41:454–458.
- Chan E, Cronstein B. (2002). Molecular action of methotrxate in inflammatory diseases. Arthritis Res 4:1–8.
- Cronstein BN. (2005). Pharmacogenetics in the rheumatic disease. Ann Rheum Dis 63:25–27.
- Friso S, Choi S, Girelli D, Mason J, Dolnikowski G, Bagley P, et al. (2002). A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99:5606–5611.
- Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat Genet 10:111–113.
- Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard J. (1998). Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T-cells. J Clin Invest 102:322–328.
- Guinotte C, Burns M, Axume J, Hata H, Urrutia T, Alamilla A, et al. (2003). Methylenetetrahydrofolate reductase C677T variant modulates folate status response to controlled folate intakes in young women. J Nutr 133:1272–1280.
- Hryniuk WM. (1972). Purineless death as a link between growth rate and cytotoxicity by methotrexate. Cancer Res 32:1506–1511.
- Hobbs CA, Sherman SL, Yi P, Hopkins SE, Torfs CP, Hine RJ, et al. (2000). Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 67:623–630.
- James S, Pogribna M, Pogribny I, Melnyk S, Hine R, Gibson J, et al. (1999). Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 70:495–501.
- Johnson LF, Fuhrman CL, Abelson HT. (1978). Resistance of resting 3t6 mouse fibroblasts to methotrexate cytotoxicity. Cancer Res 38:2408–2412.
- Li J, Kaminskas E. (1984). Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci USA 81:5694–5698.
- Matsuo K, Suzuki R, Morishima Y, Hamajima N. (2001). Attribution of post-transplantation toxicity to methotrexate regarding genotype of methylenetetrahydrofolate reductase (MTHFR) polymorphism needs further clarification. Blood 98:2283.
- Miller SA, Dykes DD, Polesky HF. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215.
- Mosnann T. (1983). Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Meth 65:(1–2):55–63.
- Shen H, Spitz MR, Wang LE, Hong WK, Wi Q. (2001). Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 10:397–401.
- Sheth J, Sheth F. (2003). Gene polymorphism and folate metabolism: a maternal risk factor for Down syndrome. Indian Pediatr 40:115–123.
- Sohn K, Croxford R, Yates Z, Lucock M, Kim Y. (2004). Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl Cancer Inst 96:134–144.
- Swierkot J, Miedzybrodzki R, Szymaniec S, Szechinski J. (2004). Activation-dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 63:599–600.
- van der Put NMJ, Gabreels F, Stevens EMB, Smeitink JAM, Trijbels FJM, et al. (1998). A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051.
- Viel A, Dall’Agnese L, Simone F, Canzonieri V, Capozzi E, Visentin MC,et al. (1997). Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. Br J Cancer 75:1105–1110.
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. (1998). A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Gen Metab 64:169–172.